



Press Release

**ULTRASPECT ANNOUNCES FDA CLEARED
HALF-DOSE CARDIAC IMAGING CAPABILITY ON XPRESS.CARDIAC™**


**UltraSPECT's Newly Added Half-Dose Capability
Offers Unprecedented Flexibility in Nuclear Cardiology:
Imaging with Half the Radiopharmaceutical Dose or at Half the Scan Time**

MERRICK, New York, June 8, 2009 —UltraSPECT, a leading provider of Nuclear Medicine image reconstruction products for enhancing the performance of gamma cameras by shortening acquisition times, enabling reduced radiopharmaceutical doses and increasing image resolution, announced today the addition of the half-dose imaging feature to the capabilities available on the Xpress.Cardiac, its half-time WBR™ image reconstruction product. This new feature can minimize radiation exposure to patients, maximizing safety for both patients and staff.

With this new, FDA-cleared feature, the Xpress.Cardiac now provides Nuclear Medicine cardiology practitioners with unprecedented flexibility in both dose and acquisition time management, revolutionizing the way Nuclear Cardiology is practiced. Depending on the patient and the physician's preference, the rest/stress studies can be acquired using either half the radiopharmaceutical dose or half the scan time.

UltraSPECT's half-dose capability has already been routinely utilized in a number of clinical settings on both shores of the Atlantic—in Europe and in the USA, with close to a 100 patients already scanned. Said Gordon DePuey, MD, Director of Nuclear Medicine at St. Luke's-Roosevelt Hospital and Professor of Radiology at Columbia University in New York City, "We have acquired scores of half-dose rest/stress scans and the images all look excellent!"

"Half-dose cardiac imaging delivers uncompromised image quality and does not in any way diminish diagnostic efficacy and certainty," stressed Allen Smith, PhD, Senior VP for Sales & Marketing UltraSPECT Inc. "In fact, the images display a higher quality than conventional full-dose FBP images, providing improved visualization of endocardial borders and wall motion segments."



Half-dose stress images acquired with 18 mCi Tc-99 Sestamibi and 11.5 min. scan time, Courtesy of St. Luke's-Roosevelt Hospital, New York, NY.



UltraSPECT's Xpress.Cardiac, Xpress3.Cardiac™, and Xpress/Xact.Bone™ products are distributed in the USA exclusively by Cardinal Health.

About UltraSPECT

UltraSPECT Ltd., based in Haifa, Israel, with U.S. offices in Merrick, NY, is a leading provider of products dedicated to enhancing the performance of Nuclear Medicine gamma cameras by shortening acquisition times, increasing image resolution, and providing the potential for reduced radiopharmaceutical doses. Compatible with most major manufacturers' cameras and workstations, these products can be installed within hours, offering a transparent interface between the camera and workstation. Shorter acquisitions improve patient comfort, reducing patient motion, and increase patient throughput without compromising image quality. Higher resolution offers improved lesion localization, raising diagnostic confidence. Lower doses reduce patient exposure to radiation. Xpress.Cardiac and Xpress3.Cardiac cut cardiac imaging times to one-half and one-quarter, respectively, without compromising image quality; Xpress/Xact.Bone can either cut bone imaging acquisition times by half, or double the image resolution. UltraSPECT products are distributed in the USA by Cardinal Health (www.cardinalhealth.com).

For more information visit our website: www.ultraspect.com,
or contact: Allen Smith, PhD, UltraSPECT Inc. at 1(888) WBR-SCAN (1-888-927-7226).